Korea, US agree on delay linkage of drug approval and patent by 3 years
Published: 2010-12-07 07:00:00
Updated: 2010-12-07 07:00:00
Korea and the United States have agreed to delay a system to suspend the approval process of a generic drug when the original developer files a complaint about patent violation against a generic maker that applies for product approval, by three years.
The two countries hammered out a revised f...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
